Skip to main content
HCPCS J2779 · Level II · Part B drug

HCPCS J2779: Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: ASP payment limits October 2026 (effective October 1, 2026); MUE and NCCI edits 2026 Q4 (effective October 1, 2026); OPPS Addendum B July 2026 (effective July 1, 2026). Next CMS release: January 1, 2027 (ASP, MUE, NCCI and OPPS quarterly updates).

Key facts for J2779

Billing unit
0.1 MG
Inj, susvimo 0.1 mg
ASP payment limit
$73.542
October 2026; -1.7% vs July 2026
Practitioner MUE
200
MAI 2
OPPS status
SI K
APC 9439
NCCI exposure
no PTP pairs
Coverage articles
1
5 states

TL;DR

HCPCS J2779 is the Level II code for Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg, billed per 0.1 MG. The Medicare Part B ASP payment limit for October 2026 is $73.542 per billing unit, down 1.7% from July 2026. The practitioner MUE allows up to 200 units per date of service (MAI 2). Under OPPS it carries status indicator K in APC 9439. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Site-specific administration routes in the descriptor tie the drug to a particular procedure code; the pairing is where NCCI column-1/column-2 edits and modifier decisions arise. The ASP crosswalk maps 2 NDCs to it, sold as Susvimo by Genentech, Inc.. 1 Medicare coverage article lists the code across 5 states, including .

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J2779 at $73.542 per 0.1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $74.795 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J2779
QuarterPayment limitPerCoinsurance
October 2026$73.5420.1 MG20%
July 2026$74.7950.1 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 2 NDCs from 1 labeler to J2779. Report the NDC in the claim's drug segment and bill the number of J2779 units that equals the quantity administered divided by 0.1 MG; the last column gives units per full package.

NDCs that crosswalk to J2779
NDCDrug nameLabelerPackage sizeBilling units / package
50242-0078-12SusvimoGenentech, Inc.0.1 × 1100
50242-0078-55SusvimoGenentech, Inc.0.1 × 1100

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for J2779. For practitioners the limit is 200 units per date of service with adjudication indicator 2, a date-of-service policy edit: the limit reflects CMS policy and units above it deny even if split across lines; appeals rarely succeed.

MUE values for J2779 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services2002 Date of Service Edit: PolicyAnatomic Consideration
Facility outpatient hospital2002 Date of Service Edit: PolicyAnatomic Consideration

NCCI edits and add-on relationships

No active practitioner PTP pair lists J2779 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

J2779 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists J2779 in their HCPCS tables, covering 5 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J2779
ArticleTitleContractor(s)StatesRelated LCD
Billing and Coding: Ranibizumab, Aflibercept and biosimilarsWellpoint FederalCT IL MN NY WIL33394

Hospital outpatient (OPPS) status

In the July 2026 OPPS Addendum B, J2779 carries status indicator K and is assigned to APC 9439, with a published national unadjusted payment of $74.80. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Common denials for J2779 and how to prevent them

CARC 16 · M119

NDC missing, invalid or not matched to the HCPCS code

CARC 151 · N362

units billed exceed the MUE for the date of service

CARC 50 · N115

diagnosis not covered by the applicable coverage article or LCD

How QuickIntell checks J2779 before the claim leaves

QuickCode validates the NDC-to-unit conversion against the current ASP crosswalk, checks units against every published MUE setting and flags PTP and add-on conflicts on the same claim. QuickRCM routes CARC 16, 151 and 50 denials on drug lines with the matching coverage article attached so the appeal starts with evidence.

Explore QuickCodeExplore QuickRCMBook a demo

Frequently asked questions — HCPCS J2779

What does HCPCS code J2779 describe?

J2779 is defined by CMS as "Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg". Each billing unit represents 0.1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

What is the Medicare reimbursement for J2779 in October 2026?

The ASP-based payment limit is $73.542 per 0.1 MG, with 20% beneficiary coinsurance. Medicare Administrative Contractors apply this limit; commercial payers use their own fee schedules. The July 2026 limit was $74.795.

How many units of J2779 can be billed per day?

The practitioner Medically Unlikely Edit is 200 units per date of service with adjudication indicator 2 (2 Date of Service Edit: Policy). MAI 2 edits are policy limits and are rarely overturned on appeal. CMS cites "Anatomic Consideration" as the rationale.

Which NDCs map to J2779?

The October 2026 ASP crosswalk lists 2 NDCs from 1 labeler: Susvimo (Genentech, Inc.). For example NDC 50242-0078-12 is a 0.1 package equal to 100 billing units. The crosswalk's billing-units-per-package figure converts each package into J2779 units.

Does J2779 have NCCI bundling edits?

No active practitioner PTP pairs list J2779 as a column-1 or column-2 code in the v323r0 release. Unit limits (MUE) and medical-necessity coverage rules still apply.

Which Medicare coverage articles mention J2779?

1 current Billing and Coding Article in the Medicare Coverage Database list J2779, covering 5 states: (Billing and Coding: Ranibizumab, Aflibercept and biosimilars).

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-01. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B and the Medicare Coverage Database. Payment limits are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.